| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2080531 | Drug Discovery Today | 2009 | 6 Pages |
Abstract
Biological medicines are a rapidly growing area of interest to many pharmaceutical companies, large and small. Under a broad definition they include not only modern high-tech products, such as monoclonal antibodies, enzymes and cytokines, but also older well-established products, such as vaccines and blood products. Despite a long history of standardisation and control of biological medicines, and an elaborate system of licensing and regulation, problems still occur because of their complexity. This review includes historical and regulatory background and three examples of problems seen with biotherapeutics: streptokinase, heparin and TGN1412.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Colin Longstaff, Colin M. Whitton, Richard Stebbings, Elaine Gray,